• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Allergan Inc. - Articles and news items


MedImmune out-licenses inflammatory diseases medicine to Allergan

Industry news / 3 October 2016 / Niamh Louise Marriott, Digital Content Producer

MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb trial for Crohn’s disease (a chronic inflammatory disease of the intestines) and is…

Irritable Bowel Syndrome

Allergen receives positive opinion for IBS drug

Industry news / 26 July 2016 / Niamh Louise Marriott, Digital Content Producer

Trubberzi is an oral medication taken to relieve the main symptoms of irritable bowel syndrome with diarrhoea (IBS-D) in adults…


FDA approves expanded label for Namzaric in Alzheimer’s disease

Industry news / 20 July 2016 / Victoria White, Digital Content Producer

Namzaric is a fixed-dose combination of memantine hydrochloride, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor…


FDA approves Allergan’s hypertension drug Byvalson

Industry news / 7 June 2016 / Victoria White, Digital Content Producer

Byvalson is the first and only fixed-dose combination (FDC) of a beta blocker (BB) and angiotensin II receptor blocker (ARB) available in the US…


Allergan and Medicines360 donate IUDs in response to Puerto Rico Zika outbreak

Industry news / 1 June 2016 / Victoria White, Digital Content Producer

Allergan and Medicines360 are to donate 10,000 units of Liletta to the CDC Foundation in response to the Zika virus outbreak in Puerto Rico…

ulipristal acetate

Ulipristal acetate meets primary endpoints in uterine fibroid study

Industry news / 9 May 2016 / Victoria White, Digital Content Producer

Allergan and Richter have announced positive results from Venus I, evaluating the efficacy and safety of ulipristal acetate in women with uterine fibroids…

waco facility

Allergan’s $200 million expansion of its Waco facility gets underway

Industry news / 26 April 2016 / Victoria White, Digital Content Producer

Allergan has broken ground on a $200 million expansion of its Texas Waco facility that will nearly double its current footprint when completed…

Topokine Therapeutics

Allergan acquires topical dermatology company Topokine Therapeutics

Industry news / 22 April 2016 / Victoria White, Digital Content Producer

Allergan has acquired Topokine Therapeutics for an upfront payment of $85 million and success-based development and sales milestones for XAF5…


Allergan and Pfizer terminate merger agreement

Industry news / 6 April 2016 / Victoria White

The decision was driven by the actions announced by the US Department of Treasury, which the companies concluded qualified as an “Adverse Tax Law Change”…


Allergan files ANDA to the FDA for generic Abraxane

Industry news / 17 March 2016 / Victoria White

Allergan believes it is a first applicant to file an ANDA for generic Abraxane and, should it be approved, may get 180 days of generic market exclusivity…


FDA accepts and grants priority review for Allergan’s Avycaz

Industry news / 24 February 2016 / Victoria White

Avycaz was first approved in the US in February 2015 for the treatment of adult patients with cIAI and cUTI caused by designated susceptible bacteria…


FDA accepts Teflaro sNDA for filing

Industry news / 16 February 2016 / Victoria White

If approved, this filing will expand the label of Teflaro beyond adults to include the treatment of children two months of age and older…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +